357 related articles for article (PubMed ID: 30076136)
1. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.
Prete A; Lo AS; Sadow PM; Bhasin SS; Antonello ZA; Vodopivec DM; Ullas S; Sims JN; Clohessy J; Dvorak AM; Sciuto T; Bhasin M; Murphy-Ullrich JE; Lawler J; Karumanchi SA; Nucera C
Clin Cancer Res; 2018 Dec; 24(23):6078-6097. PubMed ID: 30076136
[TBL] [Abstract][Full Text] [Related]
2. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
3. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in
Valvo V; Iesato A; Kavanagh TR; Priolo C; Zsengeller Z; Pontecorvi A; Stillman IE; Burke SD; Liu X; Nucera C
Thyroid; 2021 Sep; 31(9):1335-1358. PubMed ID: 33107403
[No Abstract] [Full Text] [Related]
4. Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights.
Iesato A; Li S; Roti G; Hacker MR; Fischer AH; Nucera C
J Clin Endocrinol Metab; 2021 Nov; 106(12):3569-3590. PubMed ID: 34302727
[TBL] [Abstract][Full Text] [Related]
5. Combination Treatment with the BRAF
Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
[TBL] [Abstract][Full Text] [Related]
6. Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.
Xu M; Casio M; Range DE; Sosa JA; Counter CM
Clin Cancer Res; 2018 Sep; 24(17):4271-4281. PubMed ID: 30065097
[No Abstract] [Full Text] [Related]
7. Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment.
Sadow PM; Priolo C; Nanni S; Karreth FA; Duquette M; Martinelli R; Husain A; Clohessy J; Kutzner H; Mentzel T; Carman CV; Farsetti A; Henske EP; Palescandolo E; Macconaill LE; Chung S; Fadda G; Lombardi CP; De Angelis AM; Durante O; Parker JA; Pontecorvi A; Dvorak HF; Fletcher C; Pandolfi PP; Lawler J; Nucera C
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25063326
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
Wang N; Wen J; Ren W; Wu Y; Deng C
Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF
Antonello ZA; Hsu N; Bhasin M; Roti G; Joshi M; Van Hummelen P; Ye E; Lo AS; Karumanchi SA; Bryke CR; Nucera C
Oncotarget; 2017 Oct; 8(49):84743-84760. PubMed ID: 29156680
[TBL] [Abstract][Full Text] [Related]
10. The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment.
Iesato A; Li S; Sadow PM; Abbasian M; Nazarian A; Lawler J; Nucera C
Thyroid; 2023 Jul; 33(7):835-848. PubMed ID: 37171127
[No Abstract] [Full Text] [Related]
11. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
12. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; Binessa HA; Alzahrani AS; Al-Khalaf HH; Hawwari A; Akhtar M; Assiri AM; Meyer BF; Shi Y
Oncogene; 2016 Apr; 35(15):1909-18. PubMed ID: 26477313
[TBL] [Abstract][Full Text] [Related]
13. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
14. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition.
Zhi J; Zhang P; Zhang W; Ruan X; Tian M; Guo S; Zhang W; Zheng X; Zhao L; Gao M
J Clin Endocrinol Metab; 2021 Jan; 106(1):91-107. PubMed ID: 32936899
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM
Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454
[TBL] [Abstract][Full Text] [Related]
18. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.
Bommarito A; Richiusa P; Carissimi E; Pizzolanti G; Rodolico V; Zito G; Criscimanna A; Di Blasi F; Pitrone M; Zerilli M; Amato MC; Spinelli G; Carina V; Modica G; Latteri MA; Galluzzo A; Giordano C
Endocr Relat Cancer; 2011 Dec; 18(6):669-85. PubMed ID: 21903858
[TBL] [Abstract][Full Text] [Related]
19. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
[TBL] [Abstract][Full Text] [Related]
20. BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.
Bonaldi E; Gargiuli C; De Cecco L; Micali A; Rizzetti MG; Greco A; Borrello MG; Minna E
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072194
[No Abstract] [Full Text] [Related]
[Next] [New Search]